MedTrace Logo

The Genetics of Severe Asthma in Children

NCT01238432 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 193

Last updated 2023-11-30

No results posted yet for this study

Summary

Near fatal asthma exacerbations are one of the most common causes of critical illness in children, accounting for approximately ten thousand intensive care unit (ICU) admissions per year in the United States. Even children with intermittent or mild baseline asthma can develop these severe exacerbations; however, there are few studies evaluating the risk factors associated with the development of near fatal asthma exacerbations in children. Inhaled β2-adrenergic receptor (ADRβ2) agonist therapy is the foundation of therapy for acute asthma and genetic variations of this receptor have been shown to affect response to ADRβ2 agonist therapy in this population. The investigators hypothesis is that a child's ADRβ2 genotype is associated with the development of a near fatal asthma exacerbation.

Conditions

Sponsors & Collaborators

  • UConn Health

    collaborator OTHER

  • Connecticut Children's Medical Center

    lead OTHER

Principal Investigators

  • Christopher L Carroll, MD, MS · Connecticut Children's Medical Center

Eligibility

Min Age
4 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01238432 on ClinicalTrials.gov